Literature DB >> 30670365

Re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31.

Pirus Ghadjar1, Thomas Wiegel2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30670365     DOI： 10.1016/j.eururo.2018.10.030

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  1 in total

1.  [Primary radiotherapy and short androgen deprivation therapy of 18 months may be sufficient in patients with localized prostate cancer with high-risk-factor compared to the standard of 28 to 36 months.]

Authors:  Dirk Böhmer; Felix Sedlmayer; Thomas Wiegel; Frank Wolf
Journal:  Strahlenther Onkol       Date:  2019-08       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.